- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04274712
Non-invasive Test for Acute Rejection Identification in Heart Transplanted Patients (INNOGRAFTRS001)
Non-invasive Test for Acute Rejection Identification in Heart Transplanted Patients: a Pilot Retrospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim of the study is to test INNOGRAFT Heart Suite in a clinical setting, using a previously collected set of plasma samples from patients who underwent heart transplant and routinely or symptoms-based surveillance during the period 2016- 2019.
Primary end-point
• To evaluate specificity and sensitivity of INNOGRAFT Heart Suite in identifying transplant rejection, using blood samples collected from heart transplanted patients during the same day of endomyocardial biopsy (EMB) using the histological study of EMB specimen as reference technique.
We will evaluate:
- Presence of rejection (Yes/No),
- Correct classification of rejection according to ISHLT 2004 guidelines. Rejection will be considered Yes if ISHLT 2004 grading is >1R. We chose ISHLT scale because it has been previously used in studies aimed at sensitivity assessment of other techniques (Deng et al. 2006) and because changes of therapeutic protocol are usually considered in presence of rejection grade higher than 2R.
Secondary end-points
- To evaluate the accuracy of INNOGRAFT Heart Suite in discriminating between the classes of rejection according to ISHLT 2004 guidelines using histological study of heart samples from EMB as reference technique
- To look for potential clinical modifiers of cfDNA levels, as quantitatively determined through INNOGRAFT Heart Suite, for every given rejection class. Expected modifiers are inflammatory states not related to rejection and infections. We will also consider the influence of other factors such as gender, age, pregnancy, comorbidities such as other organ failure, diabetes, cancer.
- To find if a correlation between basal donor cfDNA levels, as quantitatively determined through INNOGRAFT Heart Suite on blood samples routinely collected for surveillance or symptoms-based surveillance, and clinical outcomes exists. Clinical outcome considered will be rejection, arrythmias, graft failure, hospitalization, death.
- To find if a correlation between donor cfDNA levels, as quantitatively determined through INNOGRAFT Heart Suite on blood samples routinely collected for surveillance or symptoms-based surveillance, and parameters of cardiac function obtained through right heart catheterization exists. Cardiac catheterization will measure cardiac index, left atrium wedge, right ventricle pressure, pulmonary artery avarage pressure.
- To find if a correlation between donor cfDNA levels, as quantitatively determined through INNOGRAFT Heart Suite on blood samples routinely collected for surveillance or symptoms-based surveillance, and blood levels of calcineurin inhibitor/proliferation inhibitor (in therapeutic range/outside therapeutic range) exists in each patient and between patients. Calcineurin inhibitor, proliferation inhibitor and steroids are routine therapy for patients who underwent heart transplant. Blood levels are routinely measured in patient treated with calcineurin inhibitor or proliferation inhibitor protocols. The aim is to identify through cfDNA measure, the correct patient-specific level of immunosuppression.
- To find if differences in basal donor cfDNA levels, as quantitatively determined through INNOGRAFT Heart Suite on blood samples routinely collected for surveillance or symptoms-based surveillance, between rATG-treated and rATG-untreated patients exist. rATG is intended as induction therapy protocol before heart transplant.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Pavia, Italy, 27100
- IRCCS Fondazione Policlinico San Matteo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
To be eligible for the study, patients must fulfill all the following inclusion criteria.
- Age≥18 years;
- Heart transplanted during 2016-2019 and under surveillance for preventing acute rejection;
- Heart transplanted before 2016 but undergoing routinely or symptom-based surveillance for preventing acute rejection;
- Signed written informed consent for reuse of biosamples for research purposes; OR Signed written informed consent for study partecipation;
- Underwent at least 1 blood sampling at the same time of the EMB;
- Clinical data collected during at least 1 surveillance visit (same time of blood sampling and EMB) available;
- Availability of EMB readings for EMB performed at the same time of blood sampling.
Exclusion Criteria:
- They were subjected to re-transplantation
- They were subjected to multi-organ transplantation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison with gold standard: endomyocardial biopsy
Time Frame: 6 months
|
To evaluate specificity and sensitivity of INNOGRAFT Heart Suite in identifying transplant rejection, using blood samples collected from heart transplanted patients during the same day of endomyocardial biopsy (EMB) using the histological study of EMB specimen as reference technique.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison with ISHLT classification
Time Frame: 6 months
|
• To evaluate the accuracy of INNOGRAFT Heart Suite in discriminating between the classes of rejection according to ISHLT 2004 guidelines using histological study of heart samples from EMB as reference technique
|
6 months
|
cfDNA modifiers
Time Frame: 6 months
|
• To look for potential clinical modifiers of cfDNA levels, as quantitatively determined through INNOGRAFT Heart Suite, for every given rejection class
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Valentina Favalli, PhD, Myway Gentics Srl
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- INNOGRAFTRS001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Rejection of Cardiac Transplant
-
Medical College of WisconsinNational Heart, Lung, and Blood Institute (NHLBI); University of California... and other collaboratorsCompletedCardiovascular Disease | Heart Transplant Failure and Rejection | Cardiac Transplant Rejection | Acute Rejection of Cardiac TransplantUnited States
-
Stanford UniversityKaiser Foundation Research InstituteCompletedLung Transplant Rejection | Cardiac Transplant RejectionUnited States
-
Wake Forest University Health SciencesStanford UniversityCompletedRenal Transplant | Rejection Acute Renal | Rejection Chronic Renal | Rejection of Renal Transplant | Renin-Angiotensin SystemUnited States
-
Rabin Medical CenterCompletedChronic Rejection of Cardiac TransplantIsrael
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
Nova Scotia Health AuthorityCompletedAcute Rejection of Renal TransplantCanada
-
Seoul St. Mary's HospitalUnknownAcute Rejection of Renal TransplantKorea, Republic of
-
Lee S NguyenCompletedHeart Failure | Cardiac Death | Cardiac Allograft Vasculopathy | Acute Cellular Graft Rejection | Cardiac Transplant Disorder | Immune Tolerance | Heart Transplant Rejection | Antibody-Mediated Graft Rejection
-
Mayo ClinicNot yet recruitingCardiac Transplant RejectionUnited States
-
Loma Linda UniversityRecruitingGraft Failure | Acute Rejection of Renal TransplantUnited States
Clinical Trials on INNOGRAFT Heart Suite
-
Fondazione Don Carlo Gnocchi OnlusLithuanian University of Health Sciences; Hospital Nacional de Parapléjicos... and other collaboratorsCompletedStroke | Multiple Sclerosis | Spinal Cord Injury | Traumatic Brain DamageLithuania, Spain, Italy, Netherlands
-
Norwegian University of Science and TechnologyThe Research Council of Norway; St. Olavs Hospital; SINTEF Health ResearchCompletedAortic Aneurysm, AbdominalNorway
-
Hospital Vall d'HebronTerminated
-
Heinrich-Heine University, DuesseldorfPhilips Medical SystemsUnknownCoronary DiseaseGermany
-
Central Hospital, Nancy, FranceRecruitingAcute Ischemic StrokeFrance
-
University of California, San FranciscoMYIA Labs, Inc.TerminatedHeart Failure With Reduced Ejection FractionUnited States
-
Academisch Ziekenhuis MaastrichtRecruiting